FORM PTO-1449 (Rev. 2-32)	U.S. Department of Com Patent and Trademark		Serial No.		
(NCV. 2-02)	ratent and Trademark Office		10/580,164		
	SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				
		Applicant: Mark lan Christie			
		Filing Date: May 18, 2006	Group : 1646		

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	6,274,711	08/14/01	Golstein, et al			

FOREIGN PATENT DOCUMENTS

Examiner Initial						Trans	lation
	Document Number	Date	Country	Class	Subclass	Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	Kotake, et al., IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, The Journal of Clinical Investigation, 103:1345-1352 (1999).				
	Chabaud, et al., Contribution of Interleukin 17 to Synovium Matrix Destruction in Rheumatoid Arthritis, Cytokine, 12:1092-1099 (2000).				
EXAMINER		DATE CONSIDERED			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.